Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Pancreatic Cancer
Interventions
- DRUG: olaparib+durvalumab
Sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborators